» Articles » PMID: 33777623

Masses of the Lacrimal Gland: Evaluation and Treatment

Overview
Publisher Thieme
Date 2021 Mar 29
PMID 33777623
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Lacrimal gland lesions account for approximately 9 to 10% of all biopsied orbital masses. Potential causes include nongranulomatous and granulomatous inflammation, autoimmune disease, lymphoproliferative disorders, benign epithelial proliferation, malignant neoplasia, and metastatic disease. Inflammatory lesions and lymphoproliferative disorders are the most common and may be unilateral or bilateral; they may also be localized to the orbit or associated with systemic disease. Both benign and malignant epithelial lacrimal gland masses tend to be unilateral and involve the orbital lobe, but a more rapid onset of symptoms and periorbital pain strongly suggest malignant disease. On orbital imaging, both inflammatory and lymphoproliferative lesions conform to the globe and surrounding structures, without changes in adjacent bone, whereas epithelial lacrimal gland masses often show scalloping of the lacrimal gland fossa. Malignant epithelial lacrimal gland tumors can also have radiographic evidence of bony invasion and destruction. Masses of the lacrimal gland may be due to a broad range of pathologies, and a good working knowledge of common clinical characteristics and radiographic imaging findings is essential for diagnosis and treatment. All patients with inflammatory, lymphoproliferative, and epithelial neoplastic lesions involving the lacrimal gland require long-term surveillance for disease recurrence and progression.

Citing Articles

Optimizing surgical approaches for lacrimal gland adenoid cystic carcinoma to minimize cross-organ invasion.

Ma M, Ren T, Luan F, Li J, Wang N, Tao Y Int J Ophthalmol. 2024; 17(10):1949-1952.

PMID: 39430016 PMC: 11422378. DOI: 10.18240/ijo.2024.10.22.


Prognostic factors for lacrimal gland adenoid cystic carcinoma: a retrospective study in Chinese patients.

Yang L, Jia S, Yang J, Song X, Wang Y, Fan X Int J Ophthalmol. 2024; 17(8):1423-1430.

PMID: 39156780 PMC: 11286454. DOI: 10.18240/ijo.2024.08.06.


Advances in clinical examination of lacrimal gland.

Lin Y, Zhang Y, Shi K, Wu H, Ou S Front Med (Lausanne). 2023; 10:1257209.

PMID: 37720501 PMC: 10501785. DOI: 10.3389/fmed.2023.1257209.


Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature.

Paggi R, Mariotti F, Mencarini J, Bresci S, Campolmi I, Bartalesi F Mediterr J Hematol Infect Dis. 2023; 15(1):e2023028.

PMID: 37180207 PMC: 10171213. DOI: 10.4084/MJHID.2023.028.

References
1.
Shields J, Shields C . Malignant transformation of presumed pleomorphic adenoma of lacrimal gland after 60 years. Arch Ophthalmol. 1987; 105(10):1403-5. DOI: 10.1001/archopht.1987.01060100105037. View

2.
Leibovitch I, Prabhakaran V, Davis G, Selva D . Intraorbital injection of triamcinolone acetonide in patients with idiopathic orbital inflammation. Arch Ophthalmol. 2007; 125(12):1647-51. DOI: 10.1001/archopht.125.12.1647. View

3.
Perzin K, Jakobiec F, Livolsi V, Desjardins L . Lacrimal gland malignant mixed tumors (carcinomas arising in benign mixed tumors): a clinico-pathologic study. Cancer. 1980; 45(10):2593-2606. DOI: 10.1002/1097-0142(19800515)45:10<2593::aid-cncr2820451019>3.0.co;2-s. View

4.
Laforga J . Lacrimal gland metastasis from invasive lobular carcinoma (ER , PR , Her-2 ) as the first manifestation of disseminated breast cancer. Breast J. 2019; 26(4):762-763. DOI: 10.1111/tbj.13640. View

5.
Aronow M . Ocular adnexal lymphoma: evidence-based treatment approach. Int Ophthalmol Clin. 2014; 55(1):97-109. DOI: 10.1097/IIO.0000000000000049. View